Phibro Animal Health Corporation (PAHC) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Phibro Animal Health CFO Glenn David, at the Morgan Stanley Global Healthcare Conference on September 9, 2025, outlined the company's positive growth outlook for fiscal year 2026. A primary driver is the full annualization of the Zoetis portfolio, which contributed only eight months of sales in fiscal year 2025. This operational tailwind is anticipated to significantly enhance Phibro's financial performance in the upcoming fiscal year, underscoring the benefits of recent strategic integration.

Analysis

Phibro Animal Health's (PAHC) Chief Financial Officer, Glenn David, provided positive forward guidance at a Morgan Stanley conference, highlighting a key mechanical growth driver for fiscal year 2026. The primary catalyst identified is the full annualization of the acquired Zoetis portfolio, which will contribute a full twelve months of sales in fiscal 2026 compared to only eight months in fiscal 2025. This operational tailwind provides a clear and predictable source of top-line growth for the upcoming fiscal year, stemming directly from the successful integration of a recent transaction. While the CFO alluded to longer-term growth prospects in medicated feed additives (MFAs) and companion animal efforts, the immediate and most certain positive driver for the company's near-term financial performance is this portfolio's expanded contribution.

Key Decisions for Investors

• Investors should update their FY2026 models to incorporate the full 12-month revenue contribution from the Zoetis portfolio, which represents a confirmed, non-organic growth tailwind for Phibro Animal Health.
• The positive management commentary on the FY2026 outlook provides support for a constructive thesis, warranting a review of PAHC's valuation relative to this expected earnings uplift.
• Beyond the near-term, it is prudent to monitor for more specific details and milestones concerning the company's longer-term growth initiatives in MFAs and companion animal products to gauge the sustainability of growth beyond fiscal 2026.